Mutational Profiling in Epithelial Ovarian Cancer: A Meta-Analysis of 435 Patients Dataset

Data Description

0 represents no mutation, 1 represents a mutation

Survive relates to the survival outcome of the patient. SurviveTime is in days (7300 chosen for alive patients).

Ovarian Cancer Patients

• 361 count
• TP53, BRCA1, BRCA2, KMT2C, CDK12, CSMD3, TTN, MUC16, NF1, PALB2, RB1, PTEN, FOXM1, BRIP1, KRAS, RASA1, CHEK2, RAD50, RAD51C/D, MRE11A, NBN, FANCE, FANCD2, ATR, ATM, MSH2, PMS2, MLH1, MSH6, FAT1, FAT2, FAT3, FAT4

Uterine Cancer Patients

• 437 count
• MSH6, CDK12, PMS2, BRIP1, FAT1, CSMD3, FAT4, BRCA2, MUC16, PALB2, KRAS, BRCA1, MSH2, PTEN, TP53, NF1, KMT2C, FAT3, FANCD2, ATM, NBN, ATR, CHEK2, FANCE, MLH1

Cervical Cancer Patients

• 174 count
• CSMD3, CDK12, FAT1, BRIP1, RB1, FAT4, BRCA2, MUC16, PALB2, KRAS, TP53, PTEN, KMT2C, FAT3, BRCA1, NF1, ATM, FANCD2, NBN, ATR, MLH1